Ashwin Ravichandran

Dr. Ashwin Ravichandran


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
ARAshwin Ravichandran
Ashwin Ravichandran
JPJeffery Parker
Jeffery Parker
ENEric Novak
Eric Novak
SJSusan M. Joseph
Susan M. Joseph
JSJoel D. Schilling
Joel D. Schilling
SSScott Silvestry
Scott Silvestry

1 December 2002 in The Journal of Arthroplasty
Verified
Journal Article
Closed access
KSKhaled J Saleh
Khaled J Saleh
DDDaryll C. Dykes
Daryll C. Dykes
RTRichard L. Tweedie
Richard L. Tweedie
KMKhadeeja Mohamed
Khadeeja Mohamed
ARAshwin Ravichandran
Ashwin Ravichandran
DHDavid A. Heck
David A. Heck

9 November 2013 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
ARAshwin Ravichandran
Ashwin Ravichandran
JSJoel D. Schilling
Joel D. Schilling
ENEric Novak
Eric Novak
JPJohn Pfeifer
John Pfeifer
GEGregory A. Ewald
Gregory A. Ewald
SJSusan M. Joseph
Susan M. Joseph

10 March 2015 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
PDF file
SLShane J. LaRue
Shane J. LaRue
RGRafael Garcia‐Cortes
Rafael Garcia‐Cortes
MNMichael E. Nassif
Michael E. Nassif
JVJustin M. Vader
Justin M. Vader
SRShuddhadeb Ray
Shuddhadeb Ray
JSJoel D. Schilling
Joel D. Schilling
Summary: Introduction: Secondary pulmonary hypertension (PH) and right ventricular dysfunction are common and associated with poor prognosis in HF patients with left ventricular assist devices (LVADs). The role of pulmonary vasodilator therapy for these patients is currently unclear.Aims: We sought to evaluate the safety and clinical course of patients treated with bosentan, an endothelin receptor antagonist, after the implementation of a LVAD.Results: Between 10/2008 and 5/2011, 50 consecutive patients with mean PAP >25 mmHg were treated with bosentan after LVAD implantation for a mean duration of 15.7 (±12.4) months. Ten patients discontinued the drug for possible side effects, including three for LFT abnormalities. Comparison of baseline to 6‐month follow‐up data revealed laboratory evidence for decongestion with a decrease in bilirubin (2.3–0.6, P < 0.0001) and an improvement in pulmonary hemodynamics with echocardiographically calculated mean PVR decreasing 1.4 woods units (3.93 ± 1.53 to 2.58 ± 1.05, P < 0.0001).Conclusion: In this single‐centered retrospective case series, we provide evidence that the tolerability of bosentan in LVAD‐supported patients with secondary PH is comparable to prior experience in patients with heart failure.

1 April 2021 in Circulation: Heart Failure
Verified
Journal Article
Open access
PDF file
EBEdo Y Birati
Edo Y Birati
SNSamer S. Najjar
Samer S. Najjar
RTRyan J. Tedford
Ryan J. Tedford
BHBrian A. Houston
Brian A. Houston
SSSupriya Shore
Supriya Shore
MGMichael V. Genuardi
Michael V. Genuardi
Background: The coronavirus disease 2019 (COVID-19) pandemic continues to afflict millions of people worldwide. Patients with end-stage heart failure and left ventricular assist devices (LVADs) may be at risk for severe COVID-19 given a high prevalence of complex comorbidities and functional impaired immunity. The objective of this study is to describe the clinical characteristics and outcomes of COVID-19 in patients with end-stage heart failure and durable LVADs. Methods: The Trans-CoV-VAD registry is a multi-center registry of LVAD and cardiac transplant patients in the United States with confirmed COVID-19. Patient characteristics, exposure history, presentation, laboratory data, course, and clinical outcomes were collected by participating institutions and reviewed by a central data repository. This report represents the participation of the first 9 centers to report LVAD data into the registry. Results: A total of 40 patients were included in this cohort. The median age was 56 years (interquartile range, 46–68), 14 (35%) were women, and 21 (52%) were Black. Among the most common presenting symptoms were cough (41%), fever, and fatigue (both 38%). A total of 18% were asymptomatic at diagnosis. Only 43% of the patients reported either subjective or measured fever during the entire course of illness. Over half (60%) required hospitalization, and 8 patients (20%) died, often after lengthy hospitalizations. Conclusions: We present the largest case series of LVAD patients with COVID-19 to date. Understanding these characteristics is essential in an effort to improve the outcome of this complex patient population.

12 December 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
KMKathleen L. Morris
Kathleen L. Morris
JAJames P. Adlam
James P. Adlam
MPMathew Padanilam
Mathew Padanilam
APAmit Patel
Amit Patel
RGRafael Garcia‐Cortes
Rafael Garcia‐Cortes
ARAshwin Ravichandran
Ashwin Ravichandran